华法林遗传药理学的临床价值
摘要
华法林在临床中的应用已经有60余年,广泛用于心房纤颤、静脉栓塞、瓣膜置换术后的抗凝和预防脑卒中治疗。在2006年公布的美国心脏病协会/美国心脏协会/欧洲心脏病协会（ESC）心房纤颤治疗指南和2006年我国心房纤颤治疗建议中,均将抗凝治疗列为心房纤颤治疗的基石。
出处
《中华保健医学杂志》
2014年第2期163-164,共2页
Chinese Journal of Health Care and Medicine
参考文献19
-
1Camm AJ,Kirchhof P,Lip GY,et al. Guidelines for the manage- ment of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. European Heart J, 2010,31 (19) : 2369-2429.
-
2Takallashi H,Echizen H. Pharmaeogenetics of CYP2C9 and in- terindividual variability in anticoagulant response to warfarin[J]. Pharmaeogenomic s, 2003,3 (4) : 202-214.
-
3Xie HG,Prasad HC,Kim RB,et al. CYP2C9 allelie variants: ethnic distribution and functional significance [J]. Adv Drug Del Rev,2002,54(10) : 125721270.
-
4Ngow HA,Wan Khairina WM,Teh LK,et al. CYP2C9 polymor- phism:prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia[J]. Singapore Med J, 2009,50(5 ) : 490-493.
-
5Rost S,Fregin A,Ivaskevicius V,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor defi- ciency type 2[J]. Nature,2004,427(6974):537-541.
-
6D'Andrea G,D'Ambrosio RL, Di Perna P,et al. A polymorphismin the VKORC1 gene is associated with an interindividual vari- ability in the dose-anticoagulant effect of warfarin [J]. Blood 2005,105(2) :645-649.
-
7Rieder M J, Reiner AP,Gage BF, et al. Effect of VKORC 1 haplo- types on transcriptional regula'tion and warfarin dose [J]. N Engl J Med,2005,352(22) : 2285-2293.
-
8Limdi NA,Wadelius M,Cavallari L,et al. Warfarin pharmaeoge- netics:a single VKORC1 polymorphism is predictive of dose across 3 racial groups[J]. Blood ,2010,115(18) : 3827-3834.
-
9Borgiani P,Ciccacci C,Forte V,et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing vari- ability in the Italian population [J]. Pharmaeogenomies, 2009,10 (2) :261-266.
-
10Takeuchi F, McGinnis R, Bourgeois S,et al. A genome-wide as- sociation study confirms VKORC1,CYP2C9,and CYP4F2 as principal genetic determinants of warfarin dose[J]. Plos Genet, 2009,5(3): 1000433.
-
1孙雪,刘长河.甘露醇在脑卒中治疗中的新观念[J].黑龙江医学,2006,30(2):112-114. 被引量：11
-
2小剂量的华法林可预防静脉栓塞[J].天津药学,2003,15(3):86-86.
-
3抗癌剂增加静脉栓塞风险[J].英国医学杂志中文版,2009,12(1):29-29.
-
4某些激素替代治疗方案可能增加上皮性卵巢癌的风险[J].中华医学信息导报,2002,17(9):18-18.
-
5王吉云（摘）.新药临床开发、上市和应用——心脑血管系统药物：新的ESC心绞痛指南[J].国外药讯,2007(3):6-6.
-
6梁峰,胡大一,沈珠军,姚远.2015年欧洲心脏病协会关于室性心律失常患者治疗和心脏性猝死预防指南的解读[J].中国医院用药评价与分析,2016,16(6):721-727. 被引量：10
-
7王少石,朱鑫濮.神经保护剂在急性缺血性脑卒中治疗中的地位[J].中国全科医学,2005,8(20):1651-1653. 被引量：4
-
8岳慧杰,宋小骏,谢学建,倪江洪.137例瓣膜置换术后住院患者华法林用药的影响因素[J].中国药师,2011,14(8):1157-1159. 被引量：5
-
9吴文蓓,吴文军.临床用溶栓药物的应用和进展[J].山西医药杂志（上半月）,2010,39(1):57-58. 被引量：5
-
10严峻,侯义山,李艳,马晓燕,董艳敏,冯殿义.股动脉内注射尿激酶治疗下肢静脉栓塞[J].医药论坛杂志,2007,28(16):66-66.
